The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMW 2019 | MGUS: predicting the risk of progression
Tarek H Mouhieddine
• 13 Sep 2019
Tarek H Mouhieddine, MD, Dana-Farber Cancer Institute, Boston, MA, describes the rationale for the improved identification of high-risk patients who may be appropriate for novel clinical interventions to prevent progression or eradicate premalignant clones prior to the development of overt multiple myeloma (MM) at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.
